Publications by authors named "Catherine Coombs"

Claim this Profile
B
BETting on the future: BET inhibition for patients with lymphoma.
Timothy J Voorhees, Catherine C Coombs

Med· January 2026

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
R-DA-EPOCH Versus DA-EPOCH-R: Impact of Chemoimmunotherapy Sequencing on Treatment Outcomes in Patients With Diffuse Large B-Cell Lymphoma.
Benjamin J Lee, Shawn P Griffin, Jean Doh, Anthony Quach, Yujiao Sun, Catherine C Coombs

Clin Lymphoma Myeloma Leuk· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pirtobrutinib, a highly selective, noncovalent (reversible) BTKi in R/R follicular lymphoma: phase 1/2 BRUIN study.
Nirav N Shah, Pier Luigi Zinzani, Michael Wang, Sunita D Nasta, Ewa Lech-Maranda, Catherine C Coombs

Blood Adv· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pirtobrutinib Versus Ibrutinib in Treatment-Naïve and Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.
Jennifer A Woyach, Lugui Qiu, Sebastian Grosicki, Tomasz Wrobel, Marcelo Capra, Catherine C Coombs

J Clin Oncol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pirtobrutinib in the treatment of chronic lymphocytic leukemia or small lymphocytic lymphoma.
Syed Ibrahim, Nghia Pham, Aarushi Sahni, Samantha Sekeres, Allison Cool, Catherine C Coombs

Future Oncol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Feasibility of Bruton's Tyrosine Kinase Inhibitor Discontinuation in Chronic Lymphocytic Leukemia: The Patient Perspective.
Deborah M Stephens, Chris Stewart, Liza Avruch, Catherine C Coombs, Alexey Danilov

Clin Lymphoma Myeloma Leuk· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Erratum: Phase III Trial of Pirtobrutinib Versus Idelalisib/Rituximab or Bendamustine/Rituximab in Covalent Bruton Tyrosine Kinase Inhibitor-Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321).
Jeff P Sharman, Talha Munir, Sebastian Grosicki, Lindsey E Roeker, John M Burke, Catherine C Coombs

J Clin Oncol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
What's hidden in plain sight? Impact of clonal hematopoiesis on the risk and progression of non-hematologic cancers.
José C Martínez, Catherine C Coombs

Haematologica· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase III Trial of Pirtobrutinib Versus Idelalisib/Rituximab or Bendamustine/Rituximab in Covalent Bruton Tyrosine Kinase Inhibitor-Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321).
Jeff P Sharman, Talha Munir, Sebastian Grosicki, Lindsey E Roeker, John M Burke, Catherine C Coombs

J Clin Oncol· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical Practice Recommendations on the Role Of Allogeneic Hematopoietic Cell Transplantation and Chimeric Antigen Receptor T-Cell Therapy in Patients With Chronic Lymphocytic Leukemia on Behalf of the American Society for Transplantation and Cellular Therapy.
Mohamed A Kharfan-Dabaja, Ambuj Kumar, Javier Pinilla-Ibarz, Jennifer R Brown, Mazyar Shadman, Catherine C Coombs

Transplant Cell Ther· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Erratum: Phase III Trial of Pirtobrutinib Versus Idelalisib/Rituximab or Bendamustine/Rituximab in Covalent Bruton Tyrosine Kinase Inhibitor-Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321).
Jeff P Sharman, Talha Munir, Sebastian Grosicki, Lindsey E Roeker, John M Burke, Catherine C Coombs

J Clin Oncol· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Perspectives on Current Challenges and Emerging Approaches for Lymphoma Management From the First Bridging the Gaps in Leukemia, Lymphoma, and Multiple Myeloma Conference.
Alexey V Danilov, Craig Sauter, Tycel Phillips, Catherine C Coombs, Andrew Ip

Clin Lymphoma Myeloma Leuk· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety of Extended Pirtobrutinib Exposure in Relapsed and/or Refractory B-Cell Malignancies.
Lindsey E Roeker, Catherine C Coombs, Nirav N Shah, Wojciech Jurczak, Jennifer A Woyach

Acta Haematol· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Consensus recommendations from the 2024 Lymphoma Research Foundation workshop on treatment selection and sequencing in CLL or SLL.
Jacob D Soumerai, Jacqueline Barrientos, Inhye Ahn, Catherine Coombs, Douglas Gladstone

Blood Adv· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment Effectiveness of Venetoclax-Based Therapy After Bruton Tyrosine Kinase Inhibitors in Chronic Lymphocytic Leukemia: An International Real-World Study.
Nilanjan Ghosh, Toby A Eyre, Jennifer R Brown, Nicole Lamanna, Beenish S Manzoor, Catherine C Coombs

Am J Hematol· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pirtobrutinib monotherapy in Bruton tyrosine kinase inhibitor-intolerant patients with B-cell malignancies: results of the phase I/II BRUIN trial.
Nirav N Shah, Michael Wang, Lindsey E Roeker, Krish Patel, Jennifer A Woyach, Catherine C Coombs

Haematologica· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Interindividual variability in CYP3A-mediated venetoclax metabolism in vitro and in vivo in patients with chronic lymphocytic leukemia.
Jonghwa Lee, Jessica L Beers, Isabel Cheng, Vivian Truong, Zachary Brown, Catherine C Coombs

Clin Transl Sci· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Risk prediction for clonal cytopenia: multicenter real-world evidence.
Zhuoer Xie, Rami Komrokji, Najla Al Ali, Alexandra Regelson, Susan Geyer, Catherine C Coombs

Blood· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clonal Hematopoiesis and Clinical Outcomes in Metastatic Castration-Resistant Prostate Cancer Patients Given Androgen Receptor Pathway Inhibitors (Alliance A031201).
Jeffrey L Jensen, Olivia Bobek, Irenaeus C C Chan, Brian C Miller, David W Hillman, Catherine C Coombs

Clin Cancer Res· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clonal hematopoiesis of indeterminate potential and cardiovascular disease: Pathogenesis, clinical presentation, and future directions.
Saivaroon Gajagowni, Steven Hopkins, Yusuf Qadeer, Salim S Virani, Job A J Verdonschot, Catherine C Coombs

Prog Cardiovasc Dis· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fixed-duration pirtobrutinib plus venetoclax with or without rituximab in relapsed/refractory CLL: the phase 1b BRUIN trial.
Lindsey E Roeker, Jennifer A Woyach, Chan Y Cheah, Catherine C Coombs, Nirav N Shah

Blood· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in patients with B-cell malignancies: analysis of the Richter transformation subgroup from the multicentre, open-label, phase 1/2 BRUIN study.
William G Wierda, Nirav N Shah, Chan Y Cheah, David Lewis, Marc S Hoffmann, Catherine C Coombs

Lancet Haematol· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Are we closer to a standard of care for Richter's syndrome? Novel treatments on the horizon.
Nghia Pham, Catherine C Coombs, Susan O'Brien

Expert Rev Hematol· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Frontline Therapy of CLL-Changing Treatment Paradigms.
Catherine C Coombs

Curr Hematol Malig Rep· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comprehensive genomic profiling reveals molecular subsets of -mutated myeloid neoplasms.
Steven M Johnson, James Haberberger, Jonathan Galeotti, Lori Ramkissoon, Catherine C Coombs

Leuk Lymphoma· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis